June 17, 2025 10:56 AM EDT

Mineralys gets a mid-stage win in hypertension patients with poor renal function

Elizabeth Cairns

Senior biopharma journalist

Mineralys Therapeutics said Tuesday that its blood pressure med lorundrostat has succeeded in a Phase 2 trial in subjects with hypertension and comorbid chronic kidney …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Mineralys gets a mid-stage win in hypertension patients with poor renal function

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

FDA unveils one-year pilot to speed some new drugs to market in just one month

After a quiet year, Xaira unwraps some of its AI research, eyeing a virtual cell

Orphan drug, PBM changes are excluded from Senate version of Trump tax bill

Members of Congress oppose NIH's payment cut plan, urge appeals court to maintain block

Lilly to bolster gene editing pipeline, buying Verve for up to $1.3B

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?

Min­eralys gets a mid-stage win in hy­per­ten­sion pa­tients with poor re­nal func­tion

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

FDA un­veils one-year pi­lot to speed some new drugs to mar­ket in just one month

Af­ter a qui­et year, Xaira un­wraps some of its AI re­search, eye­ing a vir­tu­al cell

Or­phan drug, PBM changes are ex­clud­ed from Sen­ate ver­sion of Trump tax bill

Mem­bers of Con­gress op­pose NI­H's pay­ment cut plan, urge ap­peals court to main­tain block

Lil­ly to bol­ster gene edit­ing pipeline, buy­ing Verve for up to $1.3B

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

Mineralys gets a mid-stage win in hypertension patients with poor renal function

FDA unveils one-year pilot to speed some new drugs to market in just one month

After a quiet year, Xaira unwraps some of its AI research, eyeing a virtual cell

Orphan drug, PBM changes are excluded from Senate version of Trump tax bill

Members of Congress oppose NIH's payment cut plan, urge appeals court to maintain block

Lilly to bolster gene editing pipeline, buying Verve for up to $1.3B

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?